Clene Inc. (CLNN)

NASDAQ: CLNN · Real-Time Price · USD

4.230

-0.240 (-5.37%)

At close: Aug 28, 2026, 4:00 PM EDT

4.280

+0.050 (1.18%)

After-hours: Aug 28, 2026, 7:30 PM EDT

-5.37% (1D)

Market Cap	54.35M +1.2%
Revenue (ttm)	197,000 -31.1%
Net Income	-39.52M
EPS	-3.50
Shares Out	12.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,662
Open	4.430
Previous Close	4.470
Day's Range	4.170 - 4.737
52-Week Range	3.880 - 13.500
Beta	0.97
Analysts	Strong Buy
Price Target	32.20 (+661.23%)
Earnings Date	Aug 14, 2026

About CLNN

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinde... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 2012

Employees 79

Stock Exchange NASDAQ

Ticker Symbol CLNN

Website https://clene.com

Full Company Profile

Financial Performance

In 2025, Clene's revenue was $200,000, a decrease of -41.52% compared to the previous year's $342,000. Losses were -$26.17 million, -33.57% less than in 2024.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for CLNN stock is "Strong Buy." The 12-month stock price target is $32.2, which is an increase of 661.23% from the latest price.

Price Target

$32.2

(661.23% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Clene Transcript: Emerging Growth Conference

Discussions with the FDA have focused on linking neurofilament reduction to clinical benefit in ALS, with consistent biomarker and functional improvements across multiple studies. A comprehensive NDA is set for submission in early Q4, aiming for a potential commercialization decision by summer 2027.

10 days ago - Transcripts

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference. Virtual Presentation Details Date: August 19...

12 days ago - GlobeNewsWire

Clene reports Q2 EPS ($1.08), consensus (26c)

Reports Q2 revenue $90,000, consensus $48,800. “We plan to submit our new drug application for CNM-Au8 under the accelerated approval pathway for patients with ALS and believe the evidence connecting…

13 days ago - TheFly

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 Clene announces survival and functional benefit in CNM-Au8-tre...

15 days ago - GlobeNewsWire

Clene Quarterly report: Q2 2026

Clene has published its Q2 2026 quarterly earnings report on August 14, 2026.

15 days ago - Filings

Clene Earnings release: Q2 2026

Clene released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.

15 days ago - Filings

Clene Transcript: Canaccord Genuity's 46th Annual Growth Conference

Recent agency meetings clarified that a 10% neurofilament light reduction, supported by robust concurrent control data, may support accelerated approval if linked to clinical benefit. NDA filing is targeted for early Q4, with a confirmatory phase III trial and additional financing planned.

18 days ago - Transcripts

Clene to Present at The Canaccord 46th Annual Growth Conference

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopha...

4 weeks ago - GlobeNewsWire

Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’

Roth Capital analyst Jonathan Aschoff reiterated a Buy rating and $30 price target on Clene (CLNN), noting that the company ended Q1 with $12.4M in pro forma cash, enough funding…

3 months ago - TheFly

Clene reports Q1 EPS (69c), consensus (70c)

Reports Q1 revenue $15,000, consensus $33,830. “We were encouraged by the constructive dialogue during our recent Type C meeting with the FDA and appreciate the Agency’s engagement as we advance…

3 months ago - TheFly

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an ...

3 months ago - GlobeNewsWire

Clene Quarterly report: Q1 2026

Clene has published its Q1 2026 quarterly earnings report on May 14, 2026.

3 months ago - Filings

Clene Earnings release: Q1 2026

Clene released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.

3 months ago - Filings

Clene price target raised to $50 from $48 at Canaccord

Canaccord raised the firm’s price target on Clene (CLNN) to $50 from $48 and keeps a Buy rating on the shares. The firm noted the company recently announced that it…

4 months ago - TheFly

Clene Transcript: Emerging Growth Conference 92

FDA feedback supports moving forward with an NDA based on neurofilament light reduction as a surrogate endpoint, with statistically significant results achieved in ALS studies. Additional funding has been secured, and a phase III MS trial is planned for next year.

4 months ago - Transcripts